Expanded third edition of Slovene Medical Dictionary published

7. 5. 2007

Ljubljana, May 7, 2007 – The expanded third edition of the Slovene Medical Dictionary, published by the Faculty of Medicine in Ljubljana, was presented today at Lek, a Sandoz company. Lek provided financial support for the project. First, Minister of Health Dr. Andrej Bručan emphasized the importance of the dictionary not just for the medical community but for the entire Slovene nation.

In his following address, Dean of the Faculty of Medicine Dr. Dušan Šuput, M.D. stated that the dictionary was a major improvement for medical students, as it allows them to broaden their professional vocabulary in their native language.

The dictionary will be of assistance to doctors and pharmacists in their daily work with patients and also for their interpersonal communication. The instructions are well written, and the pronunciation and use guides will also be welcome to students and all professionals who write professional or lay papers or make public appearances.

In comparison with the first edition in book form in 2002, which took 23 years to prepare, involved the participation of 98 people, and included 60,700 entries and cross-references, the third edition was the work of 62 contributors (writers, editors, language consultants and computer specialists), and contains 67,319 entries and cross-references (an increase of around 11% over the first edition). The third edition took 5 years to complete. “The reason for the shorter preparation time was the consistent application of computer technology: the writers issued their contributions in digital form, the editors edited them and harmonized them with the old materials directly on computer, and communication between the writers, editors and language consultants was conducted via email. The result was increased work efficiency,” explained Editor-in-Chief Prof. Miroslav Kališnik.

The first edition was very well received by the professional community. In 2003 Lek in cooperation with the Faculty of Medicine in Ljubljana issued the second, electronic edition, on CD and in an on-line version. It was distributed free of charge to doctors, pharmacists and students. The dictionary’s editorial board at the Ljubljana Faculty of Medicine are also planning a further publication, in electronic form at the beginning of 2008. It has invited several younger contributors to participate, including some from the Faculty of Medicine in Maribor. The fundamental intention is to preserve and encourage the tradition of biomedical terminology in Slovenia.

“Scientific work and research and development have been the core of the work of Lek Pharmaceuticals for over 60 years. In addition to employing numerous professionals in various fields and developing new knowledge together with them, each year we also support the training of healthcare and pharmaceutical workers and thus continue our unswerving partnership with the healthcare community and with Slovene society. This is a part of our mission – to offer effective, safe, affordable high-quality drugs and to provide for health and a better quality of life in the broadest sense of the terms,” said Aleš Süssinger, Head of Marketing and Sales Slovenia at Lek, at the presentation.

* * *

Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biopharmaceutical products and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz’s global markets. Lek d.d. employs about 2,820 people and achieved total sales of USD 904 million in 2006. For further information please consult http://www.lek.si

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 840 active substances in over 5 000 forms worldwide. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these drugs along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to the strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and EonLabs (U.S.) and sells its products in more than 110 countries. In 2006, Sandoz employed around 21,000 people worldwide and posted sales of USD 6 billion.

Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics and leading self-medication OTC brands. In 2006, the Group’s businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For further information contact:

Katarina Klemenc Dinjaški

Corporate Communications

Lek Pharmaceuticals d.d.

Phone: + 386 1 580 22 43

Fax: + 386 1 580 24 32